The Impact of the Orphan Drug Act on the Development and Advancement of Neurological Products for Rare Diseases: A Descriptive Review

Clinical Pharmacology & Therapeutics (2010) 88 4, 449–453. doi:10.1038/clpt.2010.193

K A Burke1, S N Freeman1, M A Imoisili1 and T R Coté1
1Office of Orphan Products Development, US Food and Drug Administration, Silver Spring, Maryland, USA